Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Chief Operating Officer | February 09, 2023 | February 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Processa Pharmaceuticals, Inc.
Report date February 09, 2023 · Filed February 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,267 |
Reported balance
After 2023-02-09 transaction · row 1
1 source rowRow 1 · 2023-02-09 · Grant · Acquired 10,000 · Balance 82,267 |
| Common StockSEC Table I · non-derivative | Indirectby Elion Oncology, Inc. | 89,794 |
Reported balance
Holding disclosure · report date 2023-02-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 89,794 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2023 Filed Feb 10, 2023 22:22 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0001567619-23-002404 · doc1.xml · nonDerivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,267 Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:43 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 40,690 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000326 · doc1.xml · derivative · entry 3 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,328 Underlying: Common Stock · 40,690 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death. F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:43 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 55,107 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000326 · doc1.xml · derivative · entry 2 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,638 Underlying: Common Stock · 55,107 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death, F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death, Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:43 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,851 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000326 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,531 Underlying: Common Stock · 10,851 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment? the third anniversary of the award date? a change of control? or the reporting person's death. These restricted stock units vest on date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment? the third anniversary of the award date? a change of control? or the reporting person's death. These restricted stock units vest on date of grant. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 13:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 4,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018383 · doc1.xml · nonDerivative · entry 2 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,267 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 13:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-018383 · doc1.xml · nonDerivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Vesting of restricted stock. F1 · price: Vesting of restricted stock. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,850 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018059 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,680 Underlying: Common Stock · 10,850 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| August 16, 2022 Filed Aug 23, 2022 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-016598 · doc1.xml · nonDerivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,930 Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:40 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 20,064 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013684 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,830 Underlying: Common Stock · 20,064 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| April 01, 2022 Filed Apr 11, 2022 21:56 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 247,841 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008367 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,766 Underlying: Common Stock · 247,841 shares Expires not disclosed F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007993 · doc1.xml · derivative · entry 4 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,781 Underlying: Common Stock · 10,715 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007993 · doc1.xml · nonDerivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,930 F1 · balance_after: Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in an transaction exempt from Section 16 reporting. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000296 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,722 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 6, 2022 22:24 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000773 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,780 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| November 01, 2021 Filed Apr 4, 2022 21:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 4,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007993 · doc1.xml · derivative · entry 3 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,066 Underlying: Common Stock · 4,286 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 4,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-018171 · doc1.xml · nonDerivative · entry 2 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,387 Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-018171 · doc1.xml · nonDerivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Vesting of restricted stock. F1 · price: Vesting of restricted stock. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017831 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,024 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Jan 6, 2022 21:03 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000718 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,058 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,907 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013195 · doc1.xml · derivative · entry 3 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013195 · doc1.xml · derivative · entry 2 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,858 Underlying: Common Stock · 12,858 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals. F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013195 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022. F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022. Read SEC document |
| June 22, 2021 Filed Jun 22, 2021 22:07 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,000 | $7.03 | $14,058.40 |
DisclosureSEC source: 0001567619-21-012496 · doc1.xml · nonDerivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,127 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011982 · doc1.xml · derivative · entry 1 Floyd Robert Michael · CIK 0001828217 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Underlying: Common Stock · 8,127 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.